Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

Tauopathies Clinical Trial

Official title: Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations

Status Completed

Clinical Trial Summary

The study will investigate the ability of a new PET tracer, 18F-AV-1451, to detect depositions of a protein, called tau, in the brains of people with a mutation in the tau gene that causes deposition of the protein, and in people without the mutation. Up to three 18F-AV-1451 scans will be performed (one per year) on control subjects without MAPT mutations, presymptomatic mutation carriers, and symptomatic mutation carriers.

Clinical Trial Description

Approximately 40% of cases of Frontotemporal lobar Degeneration (FTLD) are also associated with abnormal deposition of tau protein. The purpose of this study is to image MAPT mutation carriers and their non-carrier relatives in order to study the use of this tracer as a biomarker in Frontotemporal Lobar Degeneration with tau deposition (FTLD-tau). ;

Related Conditions & MeSH terms

• Aphasia, Primary Progressive
• Frontotemporal Dementia
• Frontotemporal Dementia (FTD)
• Frontotemporal Lobar Degeneration
• Frontotemporal Lobar Degeneration (FTLD)
• Pick Disease of the Brain
• Tauopathies

• NCT number: NCT02676843
• Study type: Interventional
• Source: Columbia University
• Status: Completed
• Phase: Phase 2
• Start date: April 2016
• Completion date: November 25, 2018